Abstract
Ex vivo gene transfer to the graft before transplantation is an attractive option for circumventing systemic side effects of chronic antirejection therapy. Gene delivery of the immunomodulatory protein cytotoxic T-lymphocyte-associated protein 4–immunoglobulin (CTLA4-Ig) prevented chronic kidney rejection in a rat model of allotransplantation without the need for systemic immunosuppression. Here we generated adeno-associated virus type 2 (AAV2) and AAV9 vectors encoding for LEA29Y, an optimized version of CTLA4-Ig. Both LEA29Y vectors were equally efficient for reducing T-cell proliferation in vitro. Serotype 9 was chosen for in vivo experiments owing to a lower frequency of preformed antibodies against the AAV9 capsid in 16 non-human primate tested sera. AAV9-LEA29Y was able to transduce the kidney of non-human primates in an autotransplantation model. Expression of LEA29Y mRNA by renal cells translated into the production of the corresponding protein, which was confined to the graft but not detected in serum. Results in non-human primates represent a step forward in maintaining the portability of this strategy into clinics.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Menon MC, Murphy B . Maintenance immunosuppression in renal transplantation. Curr Opin Pharmacol 2013; 13: 662–671.
Hardinger KL, Brennan DC . Novel immunosuppressive agents in kidney transplantation. World J Transplant 2013; 3: 68–77.
Buell JF, Gross TG, Woodle ES . Malignancy after transplantation. Transplantation 2005; 80: S254–S264.
Kotton CN, Fishman JA . Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005; 16: 1758–1774.
Morales JM, Dominguez-Gil B . Cardiovascular risk profile with the new immunosuppressive combinations after renal transplantation. J Hypertens 2005; 23: 1609–1616.
Butler JA, Roderick P, Mullee M, Mason JC, Peveler RC . Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review. Transplantation 2004; 77: 769–776.
Lodhi SA, Lamb KE, Meier-Kriesche HU . Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011; 11: 1226–1235.
Lamb KE, Lodhi S, Meier-Kriesche HU . Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011; 11: 450–462.
Bretscher PA . A two-step, two-signal model for the primary activation of precursor helper T cells. Proc Natl Acad Sci USA 1999; 96: 185–190.
Yamada A, Salama AD, Sayegh MH . The role of novel T cell costimulatory pathways in autoimmunity and transplantation. J Am Soc Nephrol 2002; 13: 559–575.
Alegre ML, Frauwirth KA, Thompson CB . T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220–228.
McAdam AJ, Schweitzer AN, Sharpe AH . The role of B7 co-stimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 1998; 165: 231–247.
Ford ML, Adams AB, Pearson TC . Targeting co-stimulatory pathways: transplantation and autoimmunity. Nat Rev Nephrol 2014; 10: 14–24.
Wojciechowski D, Vincenti F . Belatacept in kidney transplantation. Curr Opin Organ Transplant 2012; 17: 640–647.
Latek R, Fleener C, Lamian V, Kulbokas E 3rd, Davis PM, Suchard SJ et al. Assessment of belatacept-mediated costimulation blockade through evaluation of CD80/86-receptor saturation. Transplantation 2009; 87: 926–933.
Tomasoni S, Azzollini N, Casiraghi F, Capogrossi MC, Remuzzi G, Benigni A . CTLA4Ig gene transfer prolongs survival and induces donor-specific tolerance in a rat renal allograft. J Am Soc Nephrol 2000; 11: 747–752.
Benigni A, Tomasoni S, Turka LA, Longaretti L, Zentilin L, Mister M et al. Adeno-associated virus-mediated CTLA4Ig gene transfer protects MHC-mismatched renal allografts from chronic rejection. J Am Soc Nephrol 2006; 17: 1665–1672.
Kells AP, Henry RA, Hughes SM, Connor B . Verification of functional AAV-mediated neurotrophic and anti-apoptotic factor expression. J Neurosci Methods 2007; 161: 291–300.
Kotterman MA, Yin L, Strazzeri JM, Flannery JG, Merigan WH, Schaffer DV . Antibody neutralization poses a barrier to intravitreal adeno-associated viral vector gene delivery to non-human primates. Gene Therapy 2015; 22: 116–126.
Boutin S, Monteilhet V, Veron P, Leborgne C, Benveniste O, Montus MF et al. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum Gene Ther 2010; 21: 704–712.
Vincenti F, Larsen C, Durrbach A, Wekerle T, Nashan B, Blancho G et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770–781.
Vincenti F, Larsen CP, Alberu J, Bresnahan B, Garcia VD, Kothari J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210–217.
Vincenti F, Rostaing L, Grinyo J, Rice K, Steinberg S, Gaite L et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374: 333–343.
Inagaki K, Fuess S, Storm TA, Gibson GA, Mctiernan CF, Kay MA et al. Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther 2006; 14: 45–53.
Bish LT, Morine K, Sleeper MM, Sanmiguel J, Wu D, Gao G et al. Adeno-associated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum Gene Ther 2008; 19: 1359–1368.
Maggiore U, Cravedi P . The marginal kidney donor. Curr Opin Organ Transplant 2014; 19: 372–380.
Arsic N, Zacchigna S, Zentilin L, Ramirez-Correa G, Pattarini L, Salvi A et al. Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. Mol Ther 2004; 10: 844–854.
Zentilin L, Marcello A, Giacca M . Involvement of cellular double-stranded DNA break binding proteins in processing of the recombinant adeno-associated virus genome. J Virol 2001; 75: 12279–12287.
Acknowledgements
We thank Kerstin Mierke for editing the manuscript. We are also grateful to the staff of CORIT and of the University of Padua for the assistance provided during the in vivo studies. This work was supported by Fondazione CARIPLO and Fondazione Cassa di Risparmio di Padova e Rovigo (CARIPARO).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Tomasoni, S., Trionfini, P., Azzollini, N. et al. AAV9-mediated engineering of autotransplanted kidney of non-human primates. Gene Ther 24, 308–313 (2017). https://doi.org/10.1038/gt.2017.21
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2017.21